Try Fund Library Premium
For Free with a 30 day trial!
Health Care Equity
Click for more information on Fundata’s FundGrade
Click for more information on Fundata’s FundGrade.
Click for more information on Fundata’s ESG Grade
Click for more information on Fundata’s ESG Grade.
2012
Click for more information on Fundata’s FundGrade
|
NAVPS (04-09-2025) |
$109.53 |
|---|---|
| Change |
$4.59
(4.37%)
|
As at March 31, 2025
As at March 31, 2025
As at March 31, 2025
Loading...
Inception Return (October 31, 1996): 10.08%
| Row Heading | Return | Annualized Return | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Mth | 3 Mth | 6 Mth | YTD | 1 Yr | 2 Yr | 3 Yr | 4 Yr | 5 Yr | 6 Yr | 7 Yr | 8 Yr | 9 Yr | 10 Yr | |
| Fund | -4.82% | -0.39% | -6.13% | -0.39% | -1.92% | 4.83% | 3.02% | 2.41% | 7.43% | 6.11% | 7.62% | 7.98% | 8.63% | 6.31% |
| Benchmark | -2.81% | 4.25% | -1.29% | 4.25% | 5.00% | 8.77% | 6.81% | 7.31% | 9.14% | 8.64% | 9.63% | 9.59% | 9.80% | 8.21% |
| Category Average | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Category Rank | 48 / 55 | 44 / 55 | 42 / 55 | 44 / 55 | 36 / 54 | 35 / 48 | 33 / 40 | 28 / 38 | 22 / 36 | 23 / 35 | 18 / 32 | 13 / 29 | 8 / 29 | 11 / 25 |
| Quartile Ranking | 4 | 4 | 4 | 4 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
| Return % | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund | -3.64% | 1.15% | 3.03% | 3.50% | 2.32% | -1.74% | -2.33% | 1.86% | -5.28% | 7.24% | -2.42% | -4.82% |
| Benchmark | -2.52% | 1.63% | 2.15% | 4.44% | 2.95% | -2.25% | -1.97% | -0.17% | -3.25% | 6.66% | 0.57% | -2.81% |
24.29% (June 2000)
-17.38% (March 2000)
| Return % | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Fund | 32.78% | -15.15% | 17.32% | 7.57% | 20.38% | 24.11% | 9.45% | -7.96% | -0.96% | 8.12% |
| Benchmark | 27.73% | -8.68% | 14.01% | 11.82% | 17.06% | 13.59% | 15.28% | -1.72% | 1.42% | 9.95% |
| Category Average | - | - | - | - | - | - | - | - | - | - |
| Quartile Ranking | 1 | 3 | 1 | 2 | 1 | 1 | 4 | 4 | 4 | 2 |
| Category Rank | 4/ 25 | 19/ 29 | 5/ 29 | 14/ 32 | 8/ 34 | 6/ 35 | 29/ 38 | 33/ 40 | 36/ 46 | 24/ 53 |
32.78% (2015)
-15.15% (2016)
| Name | Percent |
|---|---|
| US Equity | 84.40 |
| International Equity | 15.03 |
| Foreign Corporate Bonds | 0.55 |
| Cash and Equivalents | 0.01 |
| Other | 0.01 |
| Name | Percent |
|---|---|
| Healthcare | 93.40 |
| Consumer Services | 0.98 |
| Fixed Income | 0.55 |
| Financial Services | 0.26 |
| Industrial Goods | 0.16 |
| Other | 4.65 |
| Name | Percent |
|---|---|
| North America | 84.97 |
| Europe | 12.20 |
| Asia | 2.80 |
| Africa and Middle East | 0.04 |
| Other | -0.01 |
| Name | Percent |
|---|---|
| Eli Lilly and Co | 10.81 |
| UnitedHealth Group Inc | 7.17 |
| Intuitive Surgical Inc | 4.99 |
| Stryker Corp | 4.51 |
| Thermo Fisher Scientific Inc | 3.97 |
| argenx SE - ADR | 3.58 |
| Vertex Pharmaceuticals Inc | 3.30 |
| Boston Scientific Corp | 3.16 |
| Danaher Corp | 3.10 |
| Alnylam Pharmaceuticals Inc | 2.53 |
TD Health Sciences Fund - Investor Series
Median
Other - Health Care Equity
| Standard Deviation | 11.58% | 13.96% | 15.54% |
|---|---|---|---|
| Beta | 1.00% | 1.09% | 1.16% |
| Alpha | -0.04% | -0.02% | -0.03% |
| Rsquared | 0.81% | 0.82% | 0.82% |
| Sharpe | -0.02% | 0.41% | 0.36% |
| Sortino | 0.08% | 0.57% | 0.42% |
| Treynor | 0.00% | 0.05% | 0.05% |
| Tax Efficiency | 100.00% | 100.00% | 100.00% |
| Volatility |
|
|
|
| Key Ratio | 1 Yr | 3 Yr | 5 Yr | 10 Yr |
|---|---|---|---|---|
| Standard Deviation | 13.31% | 11.58% | 13.96% | 15.54% |
| Beta | 1.13% | 1.00% | 1.09% | 1.16% |
| Alpha | -0.07% | -0.04% | -0.02% | -0.03% |
| Rsquared | 0.88% | 0.81% | 0.82% | 0.82% |
| Sharpe | -0.38% | -0.02% | 0.41% | 0.36% |
| Sortino | -0.44% | 0.08% | 0.57% | 0.42% |
| Treynor | -0.04% | 0.00% | 0.05% | 0.05% |
| Tax Efficiency | - | 100.00% | 100.00% | 100.00% |
The E, S, and G scores are averaged for each security in the portfolio, to arrive at an ESG score for each security. We take the portfolio weighted average of the ESG scores for each fund and rank them against their peers to arrive at the Fundata ESG Score from 0-100.
Three scores under the Environment bucket are averaged to yield the Fundata Environment Score for each fund from 0-100: (1) Pollution Prevention, (2) Environmental Transparency, (3) Resource Efficiency.
Six scores under the Social bucket are averaged to yield the Fundata Social Score for each fund from 0-100. (1) Compensation and Satisfaction, (2) Diversity and Rights, (3) Education and Work Conditions, (4) Community and Charity, (5) Human Rights, (6) Sustainability Integration.
Three scores under the governance bucket are averaged to yield the Fundata Governance Score for each fund from 0-100: (1) Board Effectiveness, (2) Management Ethics, (3) Disclosure and Accountability.
Powered by OWL Analytics. For more information, please contact Fundata Canada.
| Start Date | October 31, 1996 |
|---|---|
| Instrument Type | Mutual Fund |
| Share Class | Commission Based Advice |
| Legal Status | Trust |
| Sales Status | Open |
| Currency | CAD |
| Distribution Frequency | Annual |
| Assets ($mil) | $1,473 |
| FundServ Code | Load Code | Sales Status |
|---|---|---|
| TDB976 |
The fundamental investment objective of the Fund is to achieve long-term capital appreciation by investing primarily in equity securities of companies located in the United States and other countries, that are engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences.
The sub-adviser seeks to achieve the fundamental investment objective of the Fund by investing at least 65% of the Fund’s total assets in common stocks of companies in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences. The sub-adviser divides the health sciences sector into four main areas: pharmaceuticals, health care services, products and devices, and biotechnology firms.
| Portfolio Manager |
TD Asset Management Inc. |
|---|---|
| Sub-Advisor |
T. Rowe Price Associates, Inc.
|
| Fund Manager |
TD Asset Management Inc. |
|---|---|
| Custodian |
CIBC Mellon Trust Company |
| Registrar |
The Toronto-Dominion Bank |
| Distributor |
TD Investment Services Inc |
| RSP Eligible | Yes |
|---|---|
| PAC Allowed | Yes |
| PAC Initial Investment | - |
| PAC Subsequent | - |
| SWP Allowed | Yes |
| SWP Min Balance | 10,000 |
| SWP Min Withdrawal | 100 |
| MER | 2.72% |
|---|---|
| Management Fee | 2.25% |
| Load | No Load |
| FE Max | - |
| DSC Max | - |
| Trailer Fee Max (FE) | - |
| Trailer Fee Max (DSC) | - |
| Trailer Fee Max (NL) | 1.00% |
| Trailer Fee Max (LL) | - |
Try Fund Library Premium
For Free with a 30 day trial!
Fund Library
